MA38688B1 - Composition solide pour administration orale contenant de l'acide ibandronique ou un sel pharmaceutiquement acceptable de celui-ci et de la vitamine d - Google Patents
Composition solide pour administration orale contenant de l'acide ibandronique ou un sel pharmaceutiquement acceptable de celui-ci et de la vitamine dInfo
- Publication number
- MA38688B1 MA38688B1 MA38688A MA38688A MA38688B1 MA 38688 B1 MA38688 B1 MA 38688B1 MA 38688 A MA38688 A MA 38688A MA 38688 A MA38688 A MA 38688A MA 38688 B1 MA38688 B1 MA 38688B1
- Authority
- MA
- Morocco
- Prior art keywords
- oral administration
- vitamin
- pharmaceutically acceptable
- acceptable salt
- ibandronic acid
- Prior art date
Links
- MPBVHIBUJCELCL-UHFFFAOYSA-N Ibandronate Chemical compound CCCCCN(C)CCC(O)(P(O)(O)=O)P(O)(O)=O MPBVHIBUJCELCL-UHFFFAOYSA-N 0.000 title abstract 2
- 229960005236 ibandronic acid Drugs 0.000 title abstract 2
- 150000003839 salts Chemical class 0.000 title abstract 2
- 229940046008 vitamin d Drugs 0.000 title abstract 2
- 239000008247 solid mixture Substances 0.000 title 1
- 239000007787 solid Substances 0.000 abstract 2
- 208000020084 Bone disease Diseases 0.000 abstract 1
- 229930003316 Vitamin D Natural products 0.000 abstract 1
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 abstract 1
- 208000022458 calcium metabolism disease Diseases 0.000 abstract 1
- 238000009472 formulation Methods 0.000 abstract 1
- 229940057917 medium chain triglycerides Drugs 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 239000003921 oil Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 235000019166 vitamin D Nutrition 0.000 abstract 1
- 239000011710 vitamin D Substances 0.000 abstract 1
- 150000003710 vitamin D derivatives Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
- A61K31/663—Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
- A61K31/593—9,10-Secocholestane derivatives, e.g. cholecalciferol, i.e. vitamin D3
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2893—Tablet coating processes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Physical Education & Sports Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Organic Chemistry (AREA)
- Rheumatology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
La présente invention concerne une composition pharmaceutique solide améliorée pour l'administration orale comprenant de l'acide ibandronique ou un sel pharmaceutiquement acceptable de celui-ci, de la vitamine d et des triglycérides à chaîne moyenne ou des huiles totalement ou partiellement hydrogénées qui confère les propriétés physico-chimiques souhaitables à une formulation solide pour l'administration orale adaptée au traitement de maladies osseuses et de troubles du métabolisme du calcium.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PT106978A PT106978A (pt) | 2013-05-31 | 2013-05-31 | Composição sólida oral contendo ácido ibandrónico e vitamina d |
PCT/PT2014/000036 WO2014193255A1 (fr) | 2013-05-31 | 2014-05-30 | Composition solide pour administration orale contenant de l'acide ibandronique ou un sel pharmaceutiquement acceptable de celui-ci et de la vitamine d |
Publications (2)
Publication Number | Publication Date |
---|---|
MA38688A1 MA38688A1 (fr) | 2017-07-31 |
MA38688B1 true MA38688B1 (fr) | 2018-08-31 |
Family
ID=50943510
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA38688A MA38688B1 (fr) | 2013-05-31 | 2014-05-30 | Composition solide pour administration orale contenant de l'acide ibandronique ou un sel pharmaceutiquement acceptable de celui-ci et de la vitamine d |
Country Status (16)
Country | Link |
---|---|
US (1) | US20160106766A1 (fr) |
EP (1) | EP3003383B1 (fr) |
BR (1) | BR112015029897A2 (fr) |
CL (1) | CL2015003468A1 (fr) |
DK (1) | DK3003383T3 (fr) |
ES (1) | ES2705074T3 (fr) |
HU (1) | HUE040666T2 (fr) |
LT (1) | LT3003383T (fr) |
MA (1) | MA38688B1 (fr) |
MX (1) | MX364680B (fr) |
PL (1) | PL3003383T3 (fr) |
PT (2) | PT106978A (fr) |
RS (1) | RS58133B1 (fr) |
SI (1) | SI3003383T1 (fr) |
TR (1) | TR201821157T4 (fr) |
WO (1) | WO2014193255A1 (fr) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2593047T3 (es) | 2006-02-03 | 2016-12-05 | Opko Renal, Llc | Tratamiento de la insuficiencia y deficiencia de vitamina D con 25-hidroxivitamina D2 y 25-hidroxivitamina D3 |
ES2670029T3 (es) | 2006-06-21 | 2018-05-29 | Opko Ireland Global Holdings, Ltd. | Terapia usando agente de repleción de la vitamina D y agente de reemplazo de la hormona de la vitamina D |
EP2762132A1 (fr) | 2007-04-25 | 2014-08-06 | Cytochroma Inc. | Compositions orales à libération contrôlée comprenant des composés de vitamine D et un véhicule cireux |
DK2148684T3 (da) | 2007-04-25 | 2013-04-22 | Cytochroma Inc | Fremgangsmåde til behandling af vitamin D-insufficiens og -deficiens |
PT2552484T (pt) | 2010-03-29 | 2020-04-03 | Opko Ireland Global Holdings Ltd | Métodos e composições para redução dos níveis de parafróides |
KR101847947B1 (ko) | 2013-03-15 | 2018-05-28 | 옵코 아이피 홀딩스 Ⅱ 인코포레이티드 | 안정화되고 변형된 비타민 d 방출 제형 |
SG10201911274TA (en) | 2014-08-07 | 2020-02-27 | Opko Ireland Global Holdings Ltd | Adjunctive therapy with 25-hydroxyvitamin d |
TWI747893B (zh) | 2016-03-28 | 2021-12-01 | 愛爾蘭商歐科愛爾蘭全球控股股份有限公司 | 維生素d治療之方法 |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100317935B1 (ko) | 1999-10-20 | 2001-12-22 | 유승필 | 대사성 골질환 치료용 약제조성물 및 이의 제조방법 |
US6468559B1 (en) * | 2000-04-28 | 2002-10-22 | Lipocine, Inc. | Enteric coated formulation of bishosphonic acid compounds and associated therapeutic methods |
US20050070504A1 (en) * | 2001-12-21 | 2005-03-31 | The Procter & Gamble Co. | Risedronate compositions and their methods of use |
AU2003226148A1 (en) | 2002-04-05 | 2003-10-27 | Merck & Co., Inc. | Method for inhibiting bone resorption with an alendronate and vitamin d formulation |
US20050261250A1 (en) * | 2004-05-19 | 2005-11-24 | Merck & Co., Inc., | Compositions and methods for inhibiting bone resorption |
US20080139514A1 (en) * | 2006-11-29 | 2008-06-12 | Subhash Pandurang Gore | Diphosphonic acid pharmaceutical compositions |
WO2008074144A1 (fr) * | 2006-12-20 | 2008-06-26 | Genpharm Ulc | Composition contenant un acide bisphosphonique combiné à de la vitamine d |
EP1972341A1 (fr) | 2007-03-23 | 2008-09-24 | Novartis AG | Compositions pharmaceutiques contenant un bisphosphonate et de la vitamine D |
EP2201937A1 (fr) * | 2008-12-23 | 2010-06-30 | Teva Pharmaceutical Industries Ltd. | Des compositions comprenant de vitamine D ou des derivatives de vitamine D |
WO2010117346A2 (fr) * | 2009-04-10 | 2010-10-14 | Mahmut Bilgic | Compositions pharmaceutiques stables à forte biodisponibilité |
IT1396937B1 (it) * | 2009-11-26 | 2012-12-20 | Bruzzese | Formulazioni di bisfosfonati e vitamina d idonee alla somministrazione intermittente per via intramuscolare e sottocutanea |
KR101230178B1 (ko) * | 2010-06-10 | 2013-02-06 | 주식회사 네비팜 | 골다공증 예방 또는 치료용 조성물 및 이의 제조방법 |
GB2502032B (en) * | 2011-03-02 | 2015-03-04 | D3 Pharma Ltd | Stable Vitamin D3 Composition |
-
2013
- 2013-05-31 PT PT106978A patent/PT106978A/pt unknown
-
2014
- 2014-05-30 US US14/894,097 patent/US20160106766A1/en not_active Abandoned
- 2014-05-30 PT PT14730606T patent/PT3003383T/pt unknown
- 2014-05-30 MX MX2015016497A patent/MX364680B/es active IP Right Grant
- 2014-05-30 PL PL14730606T patent/PL3003383T3/pl unknown
- 2014-05-30 BR BR112015029897A patent/BR112015029897A2/pt not_active Application Discontinuation
- 2014-05-30 SI SI201431025T patent/SI3003383T1/sl unknown
- 2014-05-30 HU HUE14730606A patent/HUE040666T2/hu unknown
- 2014-05-30 TR TR2018/21157T patent/TR201821157T4/tr unknown
- 2014-05-30 EP EP14730606.2A patent/EP3003383B1/fr active Active
- 2014-05-30 WO PCT/PT2014/000036 patent/WO2014193255A1/fr active Application Filing
- 2014-05-30 RS RS20181592A patent/RS58133B1/sr unknown
- 2014-05-30 DK DK14730606.2T patent/DK3003383T3/en active
- 2014-05-30 MA MA38688A patent/MA38688B1/fr unknown
- 2014-05-30 ES ES14730606T patent/ES2705074T3/es active Active
- 2014-05-30 LT LTEP14730606.2T patent/LT3003383T/lt unknown
-
2015
- 2015-11-27 CL CL2015003468A patent/CL2015003468A1/es unknown
Also Published As
Publication number | Publication date |
---|---|
ES2705074T3 (es) | 2019-03-21 |
PT3003383T (pt) | 2019-01-16 |
TR201821157T4 (tr) | 2019-02-21 |
US20160106766A1 (en) | 2016-04-21 |
MX2015016497A (es) | 2016-09-08 |
WO2014193255A1 (fr) | 2014-12-04 |
CL2015003468A1 (es) | 2016-07-22 |
RS58133B1 (sr) | 2019-02-28 |
BR112015029897A2 (pt) | 2017-07-25 |
MX364680B (es) | 2019-05-03 |
HUE040666T2 (hu) | 2019-08-28 |
SI3003383T1 (sl) | 2019-03-29 |
PT106978A (pt) | 2014-12-02 |
MA38688A1 (fr) | 2017-07-31 |
EP3003383A1 (fr) | 2016-04-13 |
DK3003383T3 (en) | 2019-01-28 |
EP3003383B1 (fr) | 2018-10-03 |
PL3003383T3 (pl) | 2019-04-30 |
LT3003383T (lt) | 2019-03-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA38688A1 (fr) | Composition solide pour administration orale contenant de l'acide ibandronique ou un sel pharmaceutiquement acceptable de celui-ci et de la vitamine d | |
MA43116B1 (fr) | Ditosylate de valbénazine et polymorphes associés | |
MA34655B1 (fr) | Dérivés de 2,3- dihydroimidazo[1,2-c]quinazoléine substitués par un aminoalcool utiles pour traiter des troubles hyperprolifératifs et des maladies associées à l'angiogenèse | |
TN2014000420A1 (fr) | Derives d'indole et d'indazole qui activent la mpk | |
MA54231A (fr) | Composés de 2-formyl-3-hydroxyphényloxyméthyle capables de moduler l'hémoglobine | |
MA34083B1 (fr) | Compositions pharmaceutques de composé spiro-oxindole pour administration topique et leur utilisation en tant qu'agents thérapeutiques | |
MA33467B1 (fr) | Promédicaments comprenant un conjugué insuline-lieur | |
MA35455B1 (fr) | (wo2013045407) dérivés d'estra-1,3,5(10),16-tétraène-3-carboxamide, procédé pour leur fabrication, préparations pharmaceutiques contenant ces substances ainsi que leur utilisation dans la fabrication de médicaments | |
MA50406B1 (fr) | Inhibiteurs pyrazole de magl | |
MA33533B1 (fr) | Compositions pharmaceutiques pour le traitement du cancer et d'autres maladies ou troubles | |
MA30539B1 (fr) | Derives de piperazinyle utiles dans le traitement de maladies induites par le recepteur gpr38. | |
MA35728B1 (fr) | Dérivés de 6,7-dihydro-5h-benzo[7]annulène, leur procédé de préparation, préparations pharmaceutiques les contenant et leur utilisation pour la fabrication de produits pharmaceutiques | |
MA34545B1 (fr) | Co-cristaux et sels d'inhibiteurs de ccr3 | |
MA35674B1 (fr) | Derives de chromone, leur procede de preparation et leurs applications therapeutiques | |
MA38425B1 (fr) | Composés bicycliques pour une utilisation comme agonistes selectifs pour le recepteur s1p1 | |
MA39447A1 (fr) | (s)-pirlindole ou ses sels pharmaceutiquement acceptables pour une utilisation en médecine | |
MA39750B1 (fr) | Dérivés d'acide aza-indol-acétique et leur utilisation comme modulateurs des récepteurs de la prostaglandine d2 | |
MA38215A1 (fr) | Composition pharmaceutique ophtalmologique topique contenant regorafenib | |
MA39448A1 (fr) | (r)-pirlindole et ses sels pharmaceutiquement acceptables destinés à un usage médical | |
MA53372B1 (fr) | Pyridopyrimidinones comme inhibiteurs du récepteur h4 de l'histamine | |
MA43793B1 (fr) | Procédé de préparation de formulations solides de mésalazine | |
MA20150424A1 (fr) | Compositions liquides orales pédiatriques contenant du nepadutant | |
MA56854B1 (fr) | Inhibiteurs de kars dépendant d'akr1c3 tricycliques | |
FR3042191B1 (fr) | Derives 1,4,8-triazaphenanthrene pour le traitement de maladies neurodegeneratives | |
MA53135B1 (fr) | Composés de c-mannoside utiles pour le traitement d'infections des voies urinaires |